RE: Buys showing as sells18 Sep 2024 13:14
TORONTO, CANADA, September 18, 2024 β Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (βAwaknβ or the βCompanyβ) a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (βAUDβ), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, June 4, 2024 and July 31, 2024, it has determined to increase the size of its previously announced non-brokered private placement financing (the βOfferingβ) from up to $1,000,000 to up to $2,000,000. Additionally, Awakn is pleased to announce the closing of a fourth tranche of the Offering through the issuance of an additional 857,143 units (the "Units") at a price of $0.46 per Unit for additional gross proceeds of $394,286 for a combined total of $1,117,142.
Each unit is comprised of one common share in the capital of the Company (each, a βCommon Shareβ) and three quarters (0.75) of one whole Common Share purchase warrant (each whole warrant, a βWarrantβ). Each Warrant entitles the holder thereof to acquire one Common Share at a price of $0.63 per Common Share for a period of five (5) years from the date of issuance. Gross proceeds from the Offering will be used to fund the companyβs general working capital